Table.
Effects of Biological Mediators and PMA on Kinetic Constantsa for Transport of Minocycline by Gingival Fibroblasts
| Treatment Condition | Kmb (μg/mL) | Vmaxb (ng/min/μg protein) |
|---|---|---|
| Control | 108 ± 4.9 | 15.2 ± 0.5 |
| FGF-2 (10 ng/mL) | 72.3 ± 3.9c | 15.3 ± 1.0 |
| PDGF (10 ng/mL) | 59.5 ± 5.2c | 16.0 ± 0.8 |
| TGFβ (30 ng/mL) | 58.8 ± 6.0c | 11.3 ± 0.8c |
| TNFα (30 ng/mL) | 77.9 ± 5.1c | 12.1 ± 0.5 |
| IL-1β (30 ng/mL) | 75.7 ± 9.8c | 13.5 ± 0.9 |
| PMA (100 nM) | 74.3 ± 6.5c | 18.4 ± 1.2 |
Fibroblasts were pre-treated with the indicated agents, with treatment times as described in the Fig. legends, after which the minocycline transport was assayed in the presence of a range of minocycline concentrations (from 14 to 150 μg/mL). Results were derived from Lineweaver-Burke analysis of transport activity observed during the rapid initial phase of uptake (3 min).
Constants are expressed as mean ± SEM of at least 5 individual experiments. Differences in the means for Km and Vmax were greater than would be expected by chance (P = 0.002, ANOVA).
Within columns, this indicates a value that is significantly different from the control (P < 0.05, Dunnett’s test).